



**Ongoing Disclosure Notice**

**Disclosure of Directors and Senior Managers Relevant Interests**

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Ryman Healthcare Limited
Date this disclosure made:	21 August 2019
Date of last disclosure:	31 August 2018

**Director or senior manager giving disclosure**

Full name(s):	Debbie McClure
Name of listed issuer:	Ryman Healthcare Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Chief Sales and Marketing Officer

**Summary of acquisition or disposal of relevant interest (excluding specified derivatives)**

<b>(1)</b>	
Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):	Beneficial owner subject to the terms of the Ryman Healthcare Limited Employee Share Scheme
<b>For that relevant interest-</b>	
Number held in class before acquisition or disposal:	112,612
Number held in class after acquisition or disposal:	125,998
Current registered holder(s):	David William Kerr & Warren James Bell as custodian for the Ryman Healthcare Limited Employee Share Scheme (held as bare trustees)
Registered holder(s) once transfers are registered:	N/A

<b>(2)</b>	
Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):	Registered holder and beneficial owner
<b>For that relevant interest-</b>	
Number held in class before acquisition or disposal:	115,722
Number held in class after acquisition or disposal:	147,071
Current registered holder(s):	Debbie McClure
Registered holder(s) once transfers are registered:	N/A

**Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)**

Type of affected derivative:	
Class of underlying financial products:	
<b>Details of affected derivative-</b>	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
<i>For that derivative, -</i>	
Parties to the derivative:	

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

**Details of transactions giving rise to acquisition or disposal**

Total number of transactions to which notice relates:

Two

**Details of transactions requiring disclosure-**

**(1)**

Date of transaction:

15 August 2019

Nature of transaction:

Transfer of legal title to 31,349 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme, from David William Kerr & Warren James Bell as custodian (as bare trustees) for the Ryman Healthcare Limited Employee Share Scheme to Debbie McClure, in accordance with such terms

Name of any other party or parties to the transaction (if known):

N/A

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

N/A

Number of financial products to which the transaction related:

31,349

**(2)**

Date of transaction:

15 August 2019

Nature of transaction:

Acquisition of beneficial interest in 44,735 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme

Name of any other party or parties to the transaction (if known):

N/A

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

\$600,000 (being \$13.40 per share)

Number of financial products to which the transaction related:

44,735

*If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—*

Whether relevant interests were acquired or disposed of during a closed period:

No

Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:

Date of the prior written clearance (if any):

**Summary of other relevant interests after acquisition or disposal:**

Class of quoted financial products:

N/A

Nature of relevant interest:

*For that relevant interest,-*

Number held in class:

Current registered holder(s):

*For a derivative relevant interest,-*

Type of derivative:

**Details of derivative,-**

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):

A statement as to whether the derivative is cash settled or physically settled:

Maturity date of the derivative (if any):

Expiry date of the derivative (if any):

The price's specified terms (if any):

Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

*For that derivative relevant interest, -*

Parties to the derivative:


If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:


**Certification**

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer:

Date of signature:


21 August 2019

or

Signature of person authorised to sign on behalf of director or officer:

Date of signature:

Name and title of authorised person:


**Notes**

Use this form to disclose all the acquisitions and disposals by a director or senior manager of a listed issuer, or of a related body corporate, or in specified derivatives. The disclosure must be made within—

(a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or

(b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.



**Ongoing Disclosure Notice**

**Disclosure of Directors and Senior Managers Relevant Interests**

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Ryman Healthcare Limited
Date this disclosure made:	21 August 2019
Date of last disclosure:	31 August 2018

**Director or senior manager giving disclosure**

Full name(s):	David Bennett
Name of listed issuer:	Ryman Healthcare Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Chief Financial Officer

**Summary of acquisition or disposal of relevant interest (excluding specified derivatives)**

<b>(1)</b>	
Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):	Beneficial owner subject to the terms of the Ryman Healthcare Limited Employee Share Scheme
<b>For that relevant interest-</b>	
Number held in class before acquisition or disposal:	73,057
Number held in class after acquisition or disposal:	96,893
Current registered holder(s):	David William Kerr & Warren James Bell as custodian for the Ryman Healthcare Limited Employee Share Scheme (held as bare trustees)
Registered holder(s) once transfers are registered:	N/A

<b>(2)</b>	
Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):	Registered holder and beneficial owner
<b>For that relevant interest-</b>	
Number held in class before acquisition or disposal:	11,825
Number held in class after acquisition or disposal:	32,724
Current registered holder(s):	David Bennett
Registered holder(s) once transfers are registered:	N/A

**Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)**

Type of affected derivative:	
Class of underlying financial products:	
<b>Details of affected derivative-</b>	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
<i>For that derivative,-</i>	
Parties to the derivative:	

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

**Details of transactions giving rise to acquisition or disposal**

Total number of transactions to which notice relates:

Two

**Details of transactions requiring disclosure-**

(1)

Date of transaction:

15 August 2019

Nature of transaction:

Transfer of legal title to 20,899 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme, from David William Kerr & Warren James Bell as custodian (as bare trustees) for the Ryman Healthcare Limited Employee Share Scheme to David Bennett, in accordance with such terms

Name of any other party or parties to the transaction (if known):

N/A

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:

N/A

Number of financial products to which the transaction related:

20,899

(2)

Date of transaction:

15 August 2019

Nature of transaction:

Acquisition of beneficial interest in 44,735 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme

Name of any other party or parties to the transaction (if known):

N/A

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:

\$600,000 (being \$13.40 per share)

Number of financial products to which the transaction related:

44,735

*If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—*

Whether relevant interests were acquired or disposed of during a closed period:

No

Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:

Date of the prior written clearance (if any):

**Summary of other relevant interests after acquisition or disposal:**

Class of quoted financial products:

N/A

Nature of relevant interest:

*For that relevant interest,-*

Number held in class:

Current registered holder(s):

*For a derivative relevant interest,-*

Type of derivative:

**Details of derivative,-**

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):

A statement as to whether the derivative is cash settled or physically settled:

Maturity date of the derivative (if any):

Expiry date of the derivative (if any):

The price's specified terms (if any):

Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:
<i>For that derivative relevant interest,-</i>
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:


**Certification**

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer:

Date of signature:


21 August 2019

or

Signature of person authorised to sign on behalf of director or officer:

Date of signature:

Name and title of authorised person:


**Notes**

Use this form to disclose all the acquisitions and disposals by a director or senior manager of a listed issuer, or of a related body corporate, or in specified derivatives. The disclosure must be made within—

(a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or

(b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.



If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

**Details of transactions giving rise to acquisition or disposal**

Total number of transactions to which notice relates:

Three

**Details of transactions requiring disclosure-**

(1)

Date of transaction:

15 August 2019

Nature of transaction:

Transfer of legal title to 31,349 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme, from David William Kerr & Warren James Bell as custodian (held as bare trustees) for the Ryman Healthcare Limited Employee Share Scheme to Barbara Reynen-Rose, in accordance with such terms

Name of any other party or parties to the transaction (if known):

N/A

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

N/A

Number of financial products to which the transaction related:

31,349

(2)

Date of transaction:

15 August 2019

Nature of transaction:

Acquisition of beneficial interest in 44,735 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme

Name of any other party or parties to the transaction (if known):

N/A

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

\$600,000 (being \$13.40 per share)

Number of financial products to which the transaction related:

44,735

(3)

Date of transaction:

15 August 2019

Nature of transaction:

On market sale

Name of any other party or parties to the transaction (if known):

N/A

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

\$5,775,387 (being \$13.40 per share)

Number of financial products to which the transaction related:

430,999

*If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—*

Whether relevant interests were acquired or disposed of during a closed period:

No

Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:

Date of the prior written clearance (if any):

**Summary of other relevant interests after acquisition or disposal:**

Class of quoted financial products:

N/A

Nature of relevant interest:

*For that relevant interest,-*

Number held in class:

Current registered holder(s):

*For a derivative relevant interest,-*

Type of derivative:

--

**Details of derivative,-**

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):

--

A statement as to whether the derivative is cash settled or physically settled:

--

Maturity date of the derivative (if any):

--

Expiry date of the derivative (if any):

--

The price's specified terms (if any):

--

Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

--

*For that derivative relevant interest,-*

Parties to the derivative:

--

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

--

**Certification**

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer:



Date of signature:

21 August 2019

or

Signature of person authorised to sign on behalf of director or officer:

--

Date of signature:

--

Name and title of authorised person:

--

**Notes**

Use this form to disclose all the acquisitions and disposals by a director or senior manager of a listed issuer, or of a related body corporate, or in specified derivatives. The disclosure must be made within—

(a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or

(b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.



**Ongoing Disclosure Notice**

**Disclosure of Directors and Senior Managers Relevant Interests**

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Ryman Healthcare Limited
Date this disclosure made:	21 August 2019
Date of last disclosure:	31 August 2018

**Director or senior manager giving disclosure**

Full name(s):	Gordon Neil MacLeod
Name of listed issuer:	Ryman Healthcare Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Chief Executive

**Summary of acquisition or disposal of relevant interest (excluding specified derivatives)**

<b>(1)</b>	
Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):	Beneficial owner subject to the terms of the Ryman Healthcare Limited Employee Share Scheme
<b>For that relevant interest-</b>	
Number held in class before acquisition or disposal:	257,094
Number held in class after acquisition or disposal:	273,418
Current registered holder(s):	David William Kerr & Warren James Bell as custodian for the Ryman Healthcare Limited Employee Share Scheme (held as bare trustees)
Registered holder(s) once transfers are registered:	N/A

<b>(2)</b>	
Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):	Registered holder and beneficial owner
<b>For that relevant interest-</b>	
Number held in class before acquisition or disposal:	364,461
Number held in class after acquisition or disposal:	387,545
Current registered holder(s):	Gordon Neil MacLeod
Registered holder(s) once transfers are registered:	N/A

**Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)**

Type of affected derivative:	
Class of underlying financial products:	
<b>Details of affected derivative-</b>	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
<i>For that derivative,-</i>	
Parties to the derivative:	

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

**Details of transactions giving rise to acquisition or disposal**

Total number of transactions to which notice relates:

Three

**Details of transactions requiring disclosure-**

(1)

Date of transaction:

15 August 2019

Nature of transaction:

Transfer of legal title to 73,146 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme, from David William Kerr & Warren James Bell as custodian (as bare trustees) for the Ryman Healthcare Limited Employee Share Scheme to Gordon Neil MacLeod, in accordance with such terms

Name of any other party or parties to the transaction (if known):

N/A

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

N/A

Number of financial products to which the transaction related:

73,146

(2)

Date of transaction:

15 August 2019

Nature of transaction:

Acquisition of beneficial interest in 89,470 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme

Name of any other party or parties to the transaction (if known):

N/A

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

\$1,200,000 (being \$13.40 per share)

Number of financial products to which the transaction related:

89,470

(3)

Date of transaction:

15 August 2019

Nature of transaction:

On market sale

Name of any other party or parties to the transaction (if known):

N/A

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

\$670,831 (being \$13.40 per share)

Number of financial products to which the transaction related:

50,062

*If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—*

Whether relevant interests were acquired or disposed of during a closed period:

No

Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:

Date of the prior written clearance (if any):

**Summary of other relevant interests after acquisition or disposal:**

Class of quoted financial products:

N/A

Nature of relevant interest:

*For that relevant interest,-*

Number held in class:

Current registered holder(s):

*For a derivative relevant interest,-*

Type of derivative:

--

**Details of derivative,-**

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):

--

A statement as to whether the derivative is cash settled or physically settled:

--

Maturity date of the derivative (if any):

--

Expiry date of the derivative (if any):

--

The price's specified terms (if any):

--

Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

--

*For that derivative relevant interest,-*

Parties to the derivative:


--

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

--

**Certification**

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.



Signature of director or officer:

21 August 2019
----------------

Date of signature:

or

Signature of person authorised to sign on behalf of director or officer:

--

Date of signature:

Name and title of authorised person:

**Notes**

Use this form to disclose all the acquisitions and disposals by a director or senior manager of a listed issuer, or of a related body corporate, or in specified derivatives. The disclosure must be made within—

(a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or

(b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.



If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

**Details of transactions giving rise to acquisition or disposal**

Total number of transactions to which notice relates:

Two

**Details of transactions requiring disclosure-**

(1)

Date of transaction:

21 August 2019

Nature of transaction:

Transfer of legal title to 20,899 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme, from David William Kerr & Warren James Bell as custodian (as bare trustees) for the Ryman Healthcare Limited Employee Share Scheme to Nicole Forster, in accordance with such terms

Name of any other party or parties to the transaction (if known):

N/A

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

N/A

Number of financial products to which the transaction related:

20,899

(2)

Date of transaction:

15 August 2019

Nature of transaction:

Acquisition of beneficial interest in 44,735 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme

Name of any other party or parties to the transaction (if known):

N/A

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

\$600,000 (being \$13.40 per share)

Number of financial products to which the transaction related:

44,735

(3)

Date of transaction:

N/A

Nature of transaction:

Name of any other party or parties to the transaction (if known):

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

Number of financial products to which the transaction related:

*If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—*

Whether relevant interests were acquired or disposed of during a closed period:

No

Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:

Date of the prior written clearance (if any):

**Summary of other relevant interests after acquisition or disposal:**

Class of quoted financial products:

Nature of relevant interest:

For that relevant interest,-

Number held in class:

Current registered holder(s):

*For a derivative relevant interest,-*

Type of derivative:

--

**Details of derivative,-**

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):

--

A statement as to whether the derivative is cash settled or physically settled:

--

Maturity date of the derivative (if any):

--

Expiry date of the derivative (if any):

--

The price's specified terms (if any):

--

Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

--

*For that derivative relevant interest,-*

Parties to the derivative:

--

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

--

**Certification**

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer:


--

Date of signature:

21 August 2019

or

Signature of person authorised to sign on behalf of director or officer:

--

Date of signature:

--

Name and title of authorised person:

--

**Notes**

Use this form to disclose all the acquisitions and disposals by a director or senior manager of a listed issuer, or of a related body corporate, or in specified derivatives. The disclosure must be made within—

(a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or

(b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.



If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

--

**Details of transactions giving rise to acquisition or disposal**

Total number of transactions to which notice relates:

Two
-----

**Details of transactions requiring disclosure-**

(1)

Date of transaction:

21 August 2019
----------------

Nature of transaction:

Transfer of legal title to 31,349 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme, from David William Kerr & Warren James Bell as custodian (as bare trustees) for the Ryman Healthcare Limited Employee Share Scheme to Tom Brownrigg, in accordance with such terms
--

Name of any other party or parties to the transaction (if known):

N/A
-----

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

N/A
-----

Number of financial products to which the transaction related:

31,349
--------

(2)

Date of transaction:

15 August 2019
----------------

Nature of transaction:

Acquisition of beneficial interest in 44,735 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme
---

Name of any other party or parties to the transaction (if known):

N/A
-----

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

\$600,000 (being \$13.40 per share)
-------------------------------------

Number of financial products to which the transaction related:

44,735
--------

(3)

Date of transaction:

N/A
-----

Nature of transaction:

--

Name of any other party or parties to the transaction (if known):

--

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

--

Number of financial products to which the transaction related:

--

*If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—*

Whether relevant interests were acquired or disposed of during a closed period:

No
----

Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:

--

Date of the prior written clearance (if any):

--

**Summary of other relevant interests after acquisition or disposal:**

Class of quoted financial products:

N/A
-----

Nature of relevant interest:

--

*For that relevant interest, -*

Number held in class:

--

Current registered holder(s):

--

*For a derivative relevant interest, -*

Type of derivative:

--

**Details of derivative,-**

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):

--

A statement as to whether the derivative is cash settled or physically settled:

--

Maturity date of the derivative (if any):

--

Expiry date of the derivative (if any):

--

The price's specified terms (if any):

--

Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

--

*For that derivative relevant interest,-*

Parties to the derivative:

--


If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

--

**Certification**

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer:



Date of signature:

21 August 2019

or

Signature of person authorised to sign on behalf of director or officer:

--

Date of signature:

--

Name and title of authorised person:

--

**Notes**

Use this form to disclose all the acquisitions and disposals by a director or senior manager of a listed issuer, or of a related body corporate, or in specified derivatives. The disclosure must be made within—

(a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or

(b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.